A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes.
Review in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
E Dale AbelDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles (E.D.A.).ORCID 0000-0001-5290-0738
Rexford S AhimaDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine (R.S.A., S.F.K.), Johns Hopkins University School of Medicine, Baltimore, MD.
Ethan J AndersonDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa (E.J.A.).ORCID 0000-0002-0113-8875
David D BergDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B., M.W.F., F.A.M., M.S.S.).ORCID 0000-0002-0366-5492
Jeffrey S BergerLeon H. Charney Division of Cardiology (J.S.B., E.A.F., M.S.G., C.G., J.D.N.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0001-8216-4647
Saumya DasCardiovascular Research Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (S.D.).ORCID 0000-0002-4521-4606
Mark W FeinbergDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B., M.W.F., F.A.M., M.S.S.).ORCID 0000-0001-9523-3859
Edward A FisherLeon H. Charney Division of Cardiology (J.S.B., E.A.F., M.S.G., C.G., J.D.N.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0001-9802-143X
Michael S GarshickLeon H. Charney Division of Cardiology (J.S.B., E.A.F., M.S.G., C.G., J.D.N.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0002-6649-3755
Chiara GiannarelliLeon H. Charney Division of Cardiology (J.S.B., E.A.F., M.S.G., C.G., J.D.N.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0003-2473-6058
Ira J GoldbergDivision of Endocrinology, Diabetes, and Metabolism (I.J.G.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0002-8701-2201
Naomi M HamburgWhitaker Cardiovascular Institute, Department of Medicine, Boston University Chobanian & Avadisian School of Medicine, MA (N.M.H.).ORCID 0000-0001-5504-5589
Sangwon F KimDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine (R.S.A., S.F.K.), Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-3887-6556
Filipe A MouraDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B., M.W.F., F.A.M., M.S.S.).
Chiadi E NdumeleDivision of Cardiology, Department of Medicine (C.E.N.), Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-1603-282X
Jonathan D NewmanLeon H. Charney Division of Cardiology (J.S.B., E.A.F., M.S.G., C.G., J.D.N.), Department of Medicine, New York University Grossman School of Medicine.ORCID 0000-0001-6855-7305
Marc S SabatineDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B., M.W.F., F.A.M., M.S.S.).ORCID 0000-0002-0691-3359
Elizabeth SelvinDepartment of Epidemiology, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD (E.S.).ORCID 0000-0001-6923-7151
Ravi ShahCardiovascular Division, Vanderbilt University Medical Center, Nashville, TN (R.S.).ORCID 0000-0002-4471-7156
Funding
Dissecting the role of CD8+ T cells in atherosclerosisR01HL153712 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GIANNARELLI, CHIARA · 2020 to 2024
$3.3M
Mechanisms of atherosclerotic cardiovascular complications in COVID19R01HL165258 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GIANNARELLI, CHIARA · 2022 to 2025
$3.1M
Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosisU01DK142281 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 2024 to 2026
$3.1M
Insulin Resistance and Myocardial AutophagyR01HL108379 · NHLBI · UNIVERSITY OF UTAH · PI ABEL, E DALE · 2011 to 2014
$1.5M
LncRNA MERRICAL, macrophage chemotaxis, and diabetes-associated atherosclerosisR01HL171239 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2024 to 2025
$1.3M
miR-130b, angiogenesis, and diabetic critical limb ischemiaR01HL167905 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2024 to 2025
$1.3M
Insulin Signaling and the Heart in DiabetesR01DK092065 · NIDDK · UNIVERSITY OF UTAH · PI ABEL, E DALE · 2010 to 2011
Despite major advances in medical therapies and prevention strategies, the risk of cardiovascular complications in patients with both type I and type II diabetes remains substantially elevated. In 2019, the American Heart Association sought applications for a Strategically Focused Research Network on Cardiometabolic Health and Type 2 Diabetes. In 2020, 4 centers were named, including Brigham and Women's Hospital, Johns Hopkins University, New York University, and the University of Iowa. These centers performed basic, translational, and clinical studies to provide insights to explain the over 2-fold risk of cardiovascular complications in diabetes. Clinical studies and studies in cells and animals aimed to uncover new mechanisms responsible for disease development. Studies using human populations sought to uncover new biomarkers to prognosticate risk. In this review, we discuss several key issues and current and developing methods to understand why diabetes drives atherosclerotic cardiovascular disease and heart failure. Both human data and experimental models are considered. We integrate a review of these topics with work from the Strategically Focused Research Network and conclude with suggestions for identifying novel risk factors and future experimental research.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes. · full record | OpenQuestion